8-K current report · filed Aug 13, 2026

Parabilis Medicines Inc (PBLS) 8-K Current Report: August 13, 2026

Item 7.01Item EX-99.1Item EX-99.2Item 2.02PBLS overview

Short answer

Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results and business highlights announced for quarter ended June 30, 2026.

Parabilis Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results and business highlights announced for quarter ended June 30, 2026
  • Full financial figures and operating details contained in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation now available on Parabilis Medicines’ investor relations website
  • Investor-facing materials likely contain current strategy, pipeline, milestones, and corporate updates
  • Exhibit 99.2 is the key source for presentation-specific information and potential market catalysts

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $52.5M, up from $34.8M, reflecting accelerating clinical and public-company spending
  • Cash, equivalents and marketable securities $1.1B, expected to fund operations into 2030 after $770.5M IPO
  • Zolucatetide Phase 3 desmoid-tumor trial targeted for 1H 2027, pending FDA alignment expected in Q4 2026
  • Regeneron collaboration delivered $125M upfront and equity consideration, with potential milestones up to $2.2B plus tiered royalties
  • R&D expense $39.4M, up from $30.1M, supporting zolucatetide trials and ERG, AR and β-catenin degrader programs

Item EX-99.2 · Exhibit EX-99.2

  • Pipeline presentation highlights zolucatetide Phase 3 desmoid-tumor trial initiation targeted for 1H 2027
  • Desmoid Phase 1/2 data: 74% ORR, 100% DCR, including one CR among 25 response-evaluable patients
  • FAP-specific cohort expected to begin in 2H 2026, broadening zolucatetide’s potential beyond desmoid tumors
  • Cash $1.1B as of June 30, 2026, expected to fund operations into 2030
  • Regeneron collaboration includes $125M upfront and equity investment, up to $2.2B milestones plus tiered royalties

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Parabilis Medicines Inc 8-K filings

Get the next PBLS 8-K as it lands

Follow PBLS for push alerts, or ask the research agent what this filing means.